Wilmington, DE, United States of America

Robert Siman

This inventor holds 15 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents, primarily in Biomarkers and Proteases. Top assignees: Cephalon, Inc., University of Pennsylvania. Active years: 1996-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Siman. Retrieved from https://idiyas.com/inventor/robert-siman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 1.9

ph-index = 8

Forward Citations = 198(Granted Patents)

Company Filing History:

University of Pennsylvania

patents

Years Active: 1996-2025

Loading Chart...

Areas of Expertise:

Blood Biomarker

Cognitive Dysfunction

Concussion

Cell Apoptosis

Protease Inhibitors

Calpain Activation

Recombinant Enzymes

Gene-Targeted Mice

Diagnosis

Prognosis

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12422433 - Blood biomarker that predicts persistent cognitive dysfunction after concussion (2025-09-23),

2. 12085565 - SNTF is a blood biomarker for the diagnosis and prognosis of sports-related concussion (2024-09-10),

3. 11761959 - Blood biomarker that predicts persistent cognitive dysfunction after concussion (2023-09-19),

4. 9952214 - SNTF is a blood biomarker for the diagnosis and prognosis of sports-related concussion (2018-04-24),

5. 7256252 - Methods for detecting cell apoptosis (2007-08-14),

6. 6057143 - Recombinant enzymatically active calpain expressed in a baculovirus (2000-05-02),

7. 6048703 - Methods for detecting cell apoptosis (2000-04-11),

8. 5990083 - Multicatalytic protease inhibitors (1999-11-23),

9. 5871712 - Methods for detecting calpain activation and identifying calpain (1999-02-16),

10. 5869336 - Recombinant enzymatically active calpain expressed in a baculovirus (1999-02-09),

11. 5830870 - Multicatalytic protease inhibitors (1998-11-03),

12. 5777194 - Gene-targeted mice with humanized A.beta. sequence and Swedish FAD (1998-07-07),

13. 5614649 - Multicatalytic protease inhibitors (1997-03-25),

14. 5550262 - Multicatalytic protease inhibitors (1996-08-27),

15. 5536639 - Methods for detecting calpain activation by detection of calpain (1996-07-16),

Title: The Innovative Contributions of Robert Siman

Introduction

Robert Siman is a notable inventor based in Wilmington, Delaware, who has made significant contributions to the field of medical technology. With a total of 15 patents to his name, Siman's work primarily focuses on advancements in diagnosing and treating mild traumatic brain injuries (mTBI). His innovative approaches have the potential to greatly enhance patient care and outcomes in sports-related injuries.

Latest Patents

Among his latest patents, Siman has developed a blood biomarker that predicts persistent cognitive dysfunction after a concussion. This invention relates to methods for providing prognosis, diagnosis, and treatment of mTBI in subjects who have not undergone computed tomography (CT) scans. It also includes monitoring the severity of brain damage resulting from TBI and determining the prognosis for individuals who have suffered from mTBI. Another significant patent involves SNTF, a blood biomarker for diagnosing and monitoring sports-related concussions. This invention assesses the severity of brain damage in subjects and helps determine their suitability to return to play after a sports-related injury.

Career Highlights

Siman has had a distinguished career, working with prominent organizations such as Cephalon, Inc. and the University of Pennsylvania. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in brain injury diagnostics.

Collaborations

Throughout his career, Siman has worked alongside notable colleagues, including Sheryl L. Meyer and Mohamed A. Iqbal. These collaborations have further enriched his research and development efforts, leading to innovative solutions in the medical field.

Conclusion

Robert Siman's contributions to the field of medical technology, particularly in the area of brain injury diagnostics, are commendable. His innovative patents and collaborations reflect his commitment to improving patient outcomes and advancing medical science.

Profile summary based on public USPTO records.